Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

84 results about "Renal transplant" patented technology

Kidney transplant or renal transplant is the process where a kidney is surgically removed from a donor and implanted into the patient. The patient may receive a kidney from a family member, a spouse or a close friend. They are known as living-related donors.

Polyomavirus cellular epitopes and uses therefor

The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of a human polyomavirus, BK virus, which is associated with polyomavirus-associated nephropathy in kidney transplant patients. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences.
Owner:CITY OF HOPE

Biomarkers for the Diagnosis of Renal Allograft and Kidney Status

The present invention relates to the identification and use of protein biomarkers with clinical relevance to kidney status and chronic renal injury or disorder. In particular, the invention provides the identity of marker proteins which are recognized by antibodies present in patients suffering from end-stage renal disorder, stable renal transplant, renal transplant glomerulopathy (TG), and interstitial fibrosis and tubular atrophy (IFTA). Methods and kits are described for using these proteins in the study and diagnosis of chronic renal transplant injury, and in the selection and / or monitoring of treatment regimens.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Application of N6-(2-ethoxy)adenosine in renal failure resistance

The invention provides application of N6-(2-ethoxy)adenosine in preparation of preparations for treating renal failure. By virtue of the N6-(2-ethoxy) adenosine, levels of inosine and urea nitrogen in renal failure and renal ischemia reperfusion injury can be obviously reduced, and renal tubular epithelial cell apoptosis and kidney inflammations are inhibited. The N6-(2-ethoxy) adenosine can be applied to multiple treatment applications of renal failure, renal transplant, renal ischemia reperfusion injury, kidney stone lithotripsy inflammations and other nephritides.
Owner:ZHEJIANG CHENGYI PAHRMACEUTICAL

Dietary supplement for renal dialysis patients

A dietary supplement which is formulated for medical patients, particularly renal dialysis patients undergoing a peritoneal renal dialysis treatment regimen. The supplement includes a powdered mixture of calcium caseinate, whey protein, L-carnitine and arginine. The ingredients are typically formulated in a powdered form which can be easily added to and ingested with various foods. The supplement provides various nutritional benefits to renal dialysis patients, including the elevation of blood carnitine and albumin levels and the reduction of blood pressure in renal transplant patients.
Owner:MILADINOV VESSELIN DANAILOV +1

Short peptide having kidney protection function as well as preparation method and application thereof

The invention relates to a short peptide having a kidney protection function as well as a preparation method and application thereof. The short peptide having the kidney protection function is characterized in that the amino acid sequence of the short peptide is QEQLERALNSS. The preparation method is characterized by comprising the following steps: successively coupling Ser, Asn, Leu, Ala, Arg, Glu, Leu, Gln, Glu and Gln on serine which is based on resin as a vector; after cracking, and settling with ice ether so as to obtain coarse peptide; and purifying with a high performance liquid chromatography (HPLC) so as to obtain the product. The invention also discloses application of the short peptide having the kidney protection function in the aspects of preparing formulations for treating renal ischemia-reperfusion injury along with acute tubular necrosis, local renal tissue inflammation and renal tubular epithelium cell apoptosis which are caused by the renal ischemia-reperfusion injury. The invention provides a novel clinic medicament for preventing and treating the renal ischemia-reperfusion injury, thereby bringing good news for patients suffering renal transplant.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Compositions and methods for assessing acute rejection in renal transplantation

InactiveUS20160348174A1Microbiological testing/measurementUrinary disorderNephrosisEnd stage renal disease
Provided herein are methods, compositions, and kits for diagnosing acute rejection of renal transplants using the gene expression profile of sets of classifier genes. Such methods and compositions are independent of external confounders such as recipient age, transplant center, RNA source, assay, cause of end-stage renal disease, co-morbidities, immunosuppression usage, and the like.
Owner:IMMUCOR GTI DIAGNOSTICS

A medicine for treating chronic renal failure and its preparing method

ActiveCN101161262AImprove kidney functionSlow down the progression of kidney failurePharmaceutical delivery mechanismUrinary disorderRenal transplantCentella
The present invention relates to a medicine for treating chronic renal failure. The chronic renal failure is the final result of various kidney diseases, but without effective western medicine in clinic yet, and dialysis therapy and renal transplantation price are expensive and not suitable for early and middle patients. The medicine whole formula of the present invention both activates and tonifies, consideration to right and evil, nourishing and releasing integrated, leading nourishing not stagnating evil, releasing not injuring right, can not only delay chronic renal failure course, but also improve or eliminate clinical symptoms, having good curative effect, lower cost characteristic. The present invention concretely is with radix astragali, poria, hedyotis diffusa, serissa foetida, pyrola calliantha, ligusticum chuanxiong, morinda officinalis how, centella asiatica, prepared rhubarb and etc. traditional Chinese medicine to prepare into compound preparation. The present invention also relates to the medicine preparation method. As pharmacological experiment shows the present invention can obviously decrease adenine causing chronic renal failure rat and nephrectomy causing chronic renal failure rat kidney function Crea and BUN value, the present invention can also obviously increase water load rat urinary volume.
Owner:江西省药物研究所

FGFR inhibitor for use in the treatment of hypophosphatemic disorders

InactiveUS20150072019A1Increasing cortical bone volumeIncreasing the thicknessOrganic active ingredientsBiocideOSTEOGLOPHONIC DYSPLASIAAutosomal recessive hypophosphatemic rickets
The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl)-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemia rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.
Owner:NOVARTIS AG

Method for treating complementary determining regions 3 (CDRs3) of T cell antigen receptor beta chains

The invention relates to a method for treating complementary determining regions 3 (CDRs3) of T cell antigen receptor beta chains. The method comprises the following steps: setting an experimental group and a control group, wherein each group comprises a plurality of parts of peripheral blood samples which are dissimilar to a human body and get away from the human body; separating T cells of the peripheral blood samples, and respectively extracting deoxyribonucleic acid (DNA) in the T cells of the peripheral blood samples; adopting a multiplex polymerase chain reaction (PCR) technique to amplify the CDRs3 of the T cell antigen receptor beta chains; carrying out high-throughput sequencing on the CDRs3 of the T cell antigen receptor beta chains, and carrying out DNA analysis on the T cell antigen receptor beta chains in the experimental group and the control group. The method for treating the CDRs3 of the T cell antigen receptor beta chains is reasonable and feasible in design, and can be used for effectively acquiring information, taken as intermediate results, about renal transplant recipients at the perioperative period and further verifying, analyzing and researching the information so as to help to study the pathogenesis of a rejection reaction and guide the individual rational application of immunosuppressive drugs, thus being beneficial to increment of short-term and long-term survival rate of renal transplant recipients after transplantation.
Owner:眭维国 +2

Ureteral stent special for kidney transplantation

The invention discloses a ureteral stent special for kidney transplantation. The ureteral stent comprises a stent body, a first curly tube, a tube opening, an intercepting tube, a second curly tube, aguide tube, a bent guide wire, a through hole, a protrusion, an intercepting tube wall, a limiting block, a rubber ring, a round hole, an intercepting cavity, a water blocking ball, a mounting cap and an elastic supporting body. The bent guide wire is made of a plastic material, so that the second coiled tube can be stably fixed in a renal pelvis of a transplanted kidney, the protrusions are allrubber protrusions and can block calculus particles, the stent body is made of a medical silica gel material, the water blocking ball is matched with the round hole, and the stent body is made of a medical silica gel material. The diameter of the water blocking ball is larger than the maximum diameter of the round hole, the phenomenon of urine backflow is prevented conveniently, the smooth layer is arranged in the stent body, a smooth inner surface is provided for the ureteral stent conveniently, smooth passing of fluid is facilitated, and the smoothness of an inner cavity of a tube body of the ureteral stent is improved.
Owner:SHANGHAI CHANGZHENG HOSPITAL

Traditional Chinese medicine extract for treating chronic nephritis, capsule and preparation method

InactiveCN101164592ALess flavorLess quantityUrinary disorderReptile material medical ingredientsWhole bodyUric acid
The present invention belong to the field of Chinese medicine technology, and discloses a Chinese medicine extract and capsule preparation for curing chronic nephritis, renal failure and urinaemia, etc. and their preparation method. Said Chinese medicine extract is made up by using 13 Chinese medicinal materials of astragalus root, American ginseng, poria, ovate atractylodex root, rehmannia flower, cordyceps, eucommia bark, lyceum berry and others through a certain preparation method. Then the obtained extract is placed into the capsule so as to obtain the invented Chinese medicine extract capsule preparation.
Owner:李政

Continuous refrigeration system for kidney transplantation operation

The invention relates to the technical field of medical instruments, in particular to a continuous refrigeration system for kidney transplantation operation. The continuous refrigeration system comprises a kidney bag, a kidney bag opening, a kidney portal opening, an in-vitro ring, an in-vivo ring, a pull wire, an inner pull ring and an outer pull ring, the kidney bag opening is formed in the upper end of the kidney bag, a transplanted kidney and smoothie mixture enters the kidney bag through the kidney bag opening, the kidney portal opening is formed in the lower end of the kidney bag, the in-vitro ring is annularly arranged at the kidney bag opening and enables the kidney bag opening to be supported and expanded, the in-vivo ring is arranged on the kidney bag in an annular mode and arranged in the body of a patient of the transplanted kidney, the outer surface of the kidney bag is connected with the pull wire, the two ends of the pull wire protrude out of the kidney bag, the lower end of the pull wire is connected with the inner pull ring, and the upper end of the pull wire is connected with the outer pull ring. The kidney bag is pulled into the in-vivo kidney anastomosis position through the inner pull ring, the kidney bag is pulled out through the outer pull ring after an operation, and the problem that a kidney supply low-temperature protection bag is inconvenient to placein a human body and take out after the operation is solved.
Owner:JIANGSU TECH-BIO-MED MEDICAL EQUIP CO LTD

A kidney transplant specimen storage device

The invention discloses a storage device for kidney transplantation specimens, which relates to the field of medical instruments and comprises a fixedly connected upper box and a lower box. The upper end of the upper box is provided with a movable box door, and the upper box is provided with a The specimen storage mechanism, the lower box is provided with a drive mechanism, the drive mechanism can drive the specimen storage mechanism to rise or fall; it also includes a cold air system, a temperature sensor and a main controller arranged on the upper box, the cold air The system, drive mechanism and temperature sensor are all electrically connected to the main controller; this design is convenient for use and safe for storage.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV

Complexes of sirolimus and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dube Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose. Furthermore, the complex of the present invention possesses exceptional stability as a redispersed solution allowing the development of liquid based formulation for transdermal and other topical applications. The invention also relates to methods of formulating and manufacturing complex according to the invention, pharmaceutical compositions containing it, its uses and methods of treatment using the complex and its compositions.
Owner:DRUGGABILITY TECH IP HOLDCO

Rat CD4 (Cluster of Differentiation 4) antibody coated magnetic beads, preparation method and application therefor and kit containing magnetic beads

The invention provides a rat CD4 antibody coated magnetic beads, a preparation method and an application therefor and a kit containing magnetic beads. The method for preparing the magnetic beads comprises the following steps of: washing the magnetic beads multiple times through different reagents, and removing the supernatant. The rat CD4 antibody coated magnetic beads can be prepared according tothe preparation method. The prepared rat CD4 antibody coated magnetic beads can be used in the kit, and used for detecting immunological rejection after rat kidney transplantation. Compared with theprior art, the invention has the advantages that the rat CD4 antibody coated magnetic beads prepared by the method for preparing the rat CD4 antibody coated magnetic beads is combined with an immune cell function measurement kit ImmuKnow TW-Cylex , and can be used for detecting the immunological rejection after the rat kidney transplantation.
Owner:福建中医药大学附属人民医院(福建省人民医院)

Method for treating complementary determining regions 3 (CDRs3) of B cell antigen receptor H chains

The invention relates to a method for treating complementary determining regions 3 (CDRs3) of B cell antigen receptor H chains. The method comprises the following steps: setting an experimental group and a control group, wherein each group comprises a plurality of parts of peripheral blood samples which are dissimilar to a human body and get away from the human body; separating B cells of the peripheral blood samples, and respectively extracting deoxyribonucleic acid (DNA) in the B cells of the peripheral blood samples; adopting a multiplex polymerase chain reaction (PCR) technique to amplify the CDRs3 of the B cell antigen receptor H chains; carrying out high-throughput sequencing on the CDRs3 of the B cell antigen receptor H chains, and carrying out DNA analysis on the B cell antigen receptor H chains in the experimental group and the control group. The method for treating the CDRs3 of the B cell antigen receptor H chains is reasonable and feasible in design, and can be used for effectively acquiring information, taken as intermediate results, about renal transplant recipients at the perioperative period and further verifying, analyzing and researching the information so as to help to study the pathogenesis of a rejection reaction and guide the individual rational application of immunosuppressive drugs, thus being beneficial to improvement of the treatment of patients with end-stage renal disease.
Owner:眭维国 +3

Kidney transplantation postoperation dynamic blood glucose monitoring system based on artificial intelligence

The invention relates to the technical field of medical instruments, and discloses a dynamic blood glucose monitoring system after kidney transplantation based on artificial intelligence, the system comprises a data acquisition and transmission module, an AI decision support module, a risk early warning and report generation module, a feedback and optimization module and a system integration module; an AI drug disturbance analysis module is arranged, when postoperation blood glucose is monitored in real time, an immunosuppressor-blood glucose dynamic response model is established, the causal relationship between the blood concentration of a specific drug and glucose metabolism is analyzed, and a drug correlation event label is labeled in real time; by means of the method, whether blood glucose fluctuation is triggered by immunosuppressor metabolism abnormality or not can be accurately recognized, it is avoided that drug-induced hyperglycemia is misjudged as an dietary event, the accuracy of treatment intervention decision making is guaranteed, and the rejection risk is reduced.
Owner:THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIV

Polyomavirus cellular epitopes and uses therefor

The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of a human polyomavirus, BK virus, which is associated with polyomavirus-associated nephropathy in kidney transplant patients. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences.
Owner:CITY OF HOPE

FGFR inhibitor for use in the treatment of hypophosphatemic disorders

ActiveUS20170007606A1Organic active ingredientsPeptide/protein ingredientsOSTEOGLOPHONIC DYSPLASIAAutosomal dominant hypophosphatemic rickets
The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.
Owner:NOVARTIS AG

Assessing transplant rejection status by analysis of t-cell receptor subunit repertoire diversity

Disclosed are novel methods of assessing transplant rejection status in a transplant recipient, such as a kidney transplant recipient. The diagnostic method identifies stable subjects, subjects undergoing cell mediated rejection processes, and subjects undergoing antibody mediated rejection processes using measurement of TCR subunit repertoire diversity. The proportion of unique TCR alpha and beta subunit sequences to total unique TCR subunit sequences (total sequences for alpha, beta, delta, and gamma subunits) provides a diagnostic measure that can identify stable subjects, subjects undergoing cell mediated rejection processes, and subjects undergoing antibody mediated rejection processes. Methods of treatment include administration of a suitable treatment if antibody mediated rejection or cell mediated rejection is detected.
Owner:RGT UNIV OF CALIFORNIA

Blood vessel anastomat for kidney transplantation operation

The invention belongs to the technical field of medical instruments, and discloses a blood vessel anastomat for a kidney transplantation operation. An inner tube main body comprises a left inner tube; fixed teeth fixedly connected with the left inner tube are arranged on the left inner tube; a middle tube fixedly connected with the left inner tube is arranged on the left inner tube; a right inner tube fixedly connected with the middle tube is arranged on the middle tube; fixing teeth fixedly connected with the right inner tube are arranged on the right inner tube; and hollow grids are arranged on the left inner tube, the middle tube and the right inner tube. According to the blood vessel anastomat, through the inner tube main body made of a shape memory material, the left inner tube and the right inner tube are expanded at phase-change temperature, and the middle tube is shrunk at the phase-change temperature, to make blood vessels on the two sides attached.
Owner:PEOPLES HOSPITAL OF HENAN PROV

Gene expression profiles associated with sub-clinical kidney transplant rejection

By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with subclinical acute rejection (subAR). These genes sets are useful for diagnosis, prognosis, monitoring of subAR.
Owner:THE SCRIPPS RES INST +1

Kidney transplantation specimen storage device

The invention discloses a kidney transplantation specimen storage device, and relates to the field of medical instruments. The kidney transplantation specimen storage device comprises an upper box body and a lower box body which are fixedly connected, wherein the upper end of the upper box body is provided with a movable box door, a specimen containing mechanism is arranged in the upper box body,a driving mechanism is arranged in the lower box body, and the driving mechanism can drive the specimen containing mechanism to ascend or descend; and the kidney transplantation specimen storage device further comprises a cold air system, a temperature sensor and a main controller, the temperature sensor and the main controller are arranged on the upper box body, and the cold air system, the driving mechanism and the temperature sensor are electrically connected with the main controller. Through the design, the kidney transplantation specimen storage device is convenient to use and safe in storage.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV

Retractor device for kidney transplantation surgery

The application provides a retractor for kidney transplantation surgery and relates to the technical field of medical auxiliary devices.The retractor comprises a retractor assembly and control pliers for controlling the opening and closing of the retractor assembly.The control pliers comprise two plier heads, and the retractor assembly comprises two retractor parts connected to the corresponding plier heads respectively.Two sets of the retractor assembly and the control pliers are symmetrically arranged, and a first driving device is arranged between the two sets of control pliers to maintain and / or adjust the distance between the two control pliers.A second driving device is arranged inside the control pliers to adjust the opening and closing angle of the control pliers.Both the first driving device and the second driving device are hydraulic telescopic elements.The application greatly improves the efficiency of the surgery and shortens the surgery time.In the process of the surgery, the surgery posture of the patient and the related equipment can be greatly adjusted without the need for secondary traction positioning, and the normal performance of the surgery is not affected by the great change of the surgery window.
Owner:GUANGDONG NO 2 PROVINCIAL PEOPLES HOSPITAL

Rnai agents for inhibiting expression of complement factor b (CFB), pharmaceutical compositions thereof, and methods of use

The present disclosure relates to RNAi agents able to inhibit Complement Factor B (CFB) gene expression. Also disclosed are pharmaceutical compositions that include CFB RNAi agents and methods of use thereof. The CFB RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the in vivo delivery to hepatocyte cells. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), Anti-Glomerular Basement Membrane disease (anti-GBM), ischemia reperfusion injury and T-cell mediated rejection (TCMR) in kidney transplantation, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD), including early and / or intermediate AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated diseases.
Owner:ARROWHEAD PHARMACEUTICALS INC

Crystalline forms of n-(1-(TERT-butyl)-1h-pyrazol-4-YL)-2-(4-((6-((methylsulfonyl)quinolin-4-YL)OXY)-3-methylphenyl)acetamide and salts thereof as RIPK2 inhibitors for the treatment of inflammatory diseases

PCT designated stageWO2025250650A1Organic active ingredientsNervous disorderDementia with Lewy bodiesAutoimmune condition
The present disclosure relates to crystalline forms of N-(l-(tert-butyl)-lH-pyrazol-4-yl)-2-( 4-((6-((methylsulfonyl)quinolin-4-yl)oxy)-3-methylphenyl)acetamide of formula (II) and crystalline forms of salts thereof. The compound of formula (II) is a RIPK2 inhibitor for the treatment of e.g. inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative diseases or cancer, and more specifically for the treatment of inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, rheumatoid arthritis, inflammatory arthritis, peritonitis, ischemia reperfusion injury in kidney transplant, non-alcohol steatohepatitis, alcohol steatohepatitis, insulin-resistant type 2 diabetes, allergic rhinitis, asthma, atopic dermatitis, Sjogren's syndrome, spondyloarthritis, ankylosing spondylitis, pemphigus vulgaris, idiopathic plasmacytic lymphadenopathy, atherosclerosis, myocardial infarction, thrombosis, alpha-synucleinopathy, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Alzheimer's disease, amyotrophic lateral sclerosis, and chronic obstructive pulmonary disease
Owner:ODYSSEY THERAPEUTICS INC

Acute kidney injury diagnostic marker based on transcription factor MAFF and application

Experiments prove that the expression of the MAFF transcription factor in an acute kidney injury sample of a patient caused by a kidney transplantation operation is up-regulated, the expression of the MAFF transcription factor in an acute kidney injury model of a mouse is remarkably up-regulated, and the MAFF transcription factor is specifically and highly expressed in renal tubular epithelial cells. Based on the discovery, the invention provides application of MAFF as a biomarker in diagnosis of acute kidney injury. The invention provides a new technical means for early diagnosis of acute kidney injury, and has important clinical application value.
Owner:HUADU DISTRICT GUANGZHOU CITY PEOPLES HOSPITAL

CVC fixing protective sleeve convenient to maintain and used for kidney transplantation nursing

According to the technical scheme, the CVC fixing protective sleeve convenient to maintain and used for kidney transplantation nursing is characterized in that the CVC fixing protective sleeve comprises a pasting film, a medical silica gel adhesion layer is arranged on the bottom face of the pasting film, a dressing piece is arranged on the top face of the pasting film, and a bottom plate is fixedly installed on the top face of the dressing piece; a through hole is formed in the top surface of the bottom plate, a waterproof ring is arranged in the through hole, a top plate is arranged on the top surface of the bottom plate, a T-shaped groove is formed in one side of the top plate, and a fixing block is arranged in the T-shaped groove; when the CVC catheter is used and pulled by external force, deformation of the fixing block directly acts on the piezoelectric film on the inner side to enable the piezoelectric film to generate mechanical strain, the piezoelectric film generates a piezoelectric effect under the strain effect, electric dipole arrangement in the piezoelectric film changes, and charge accumulation is generated on the surface of the film; the microprocessor triggers the acousto-optic alarm to remind medical staff.
Owner:THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIV

FGFR inhibitor for use in the treatment of hypophosphatemic disorders

InactiveUS20240398798A1Organic active ingredientsMetabolism disorderDiseaseOSTEOGLOPHONIC DYSPLASIA
The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.
Owner:NOVARTIS AG